Jacob A. Frenkel - 10 Dec 2021 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role
Director
Signature
/s/ Jacob A. Frenkel
Issuer symbol
BCLI
Transactions as of
10 Dec 2021
Net transactions value
$0
Form type
4
Filing time
10 Dec 2021, 19:02:28 UTC
Next filing
08 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCLI Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 10 Dec 2021 Common Stock 50,000 $0.7500 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2021 until fully vested and exercisable on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date.